Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children

Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children

BackgroundA blood-stage vaccine targeting the erythrocytic-stages of the malaria parasite Plasmodium falciparum could play a role to protect against clinical disease. Antibodies against the P. falciparum serine repeat antigen 5 (SE47 and SE36 domains) correlate well with the absence of clinical symp...

Full description

Bibliographic Details
Main Authors: Edith Christiane Bougouma, Nirianne Marie Q. Palacpac, Alfred B. Tiono, Issa Nebie, Alphonse Ouédraogo, Sophie Houard, Masanori Yagi, Sam Aboubacar Coulibaly, Amidou Diarra, Takahiro Tougan, Amidou Z. Ouedraogo, Issiaka Soulama, Nobuko Arisue, Jean Baptiste Yaro, Flavia D’Alessio, Odile Leroy, Simon Cousens, Toshihiro Horii, Sodiomon B. Sirima
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
SE36
malaria blood-stage vaccine
serine repeat antigen
SERA5
Plasmodium falciparum
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.978591/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.978591/full

Similar Items